{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Overall survival of participants reported after 2 years.","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"1 and 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}